1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma
Eckard Hamelmann, Attilio Boner, Jonathan Bernstein, Petra Moroni-Zentgraf, Michael Engel, Mandy Avis, Anna Unseld, Mark Vandewalker
European Respiratory Journal 2014 44: 1889; DOI:
Eckard Hamelmann
2Department of Child and Adolescent Medicine, St. Josef Hospital, Bochum, Germany
Attilio Boner
1Pediatric Department, University of Verona, Verona, Italy
Jonathan Bernstein
3Department of Internal Medicine, University of Cincinnati Medical Sciences Building, Cincinnati, OH,
Petra Moroni-Zentgraf
4TA Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany
Michael Engel
4TA Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany
Mandy Avis
5Trial Clinical Monitor, Boehringer Ingelheim bv, Alkmaar, Netherlands
Anna Unseld
6Global Biometrics and Clinical Applications, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany
Mark Vandewalker
7Medical Director, Clinical Research of the Ozarks, Columbia, MO,
Vol 44 Issue Suppl 58
Table of Contents
1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma
Eckard Hamelmann, Attilio Boner, Jonathan Bernstein, Petra Moroni-Zentgraf, Michael Engel, Mandy Avis, Anna Unseld, Mark Vandewalker
European Respiratory Journal Sep 2014, 44 (Suppl 58) 1889;
1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma
Eckard Hamelmann, Attilio Boner, Jonathan Bernstein, Petra Moroni-Zentgraf, Michael Engel, Mandy Avis, Anna Unseld, Mark Vandewalker
European Respiratory Journal Sep 2014, 44 (Suppl 58) 1889;